



Organizers:



With the collaboration of:



INTERNATIONAL SYMPOSIUM ON CTL AND IMMUNOSTIMULATION

PLACE
Aula Magna CIMA
Universidad de Navarra
Avda. Pío XII, 55. 31008 Pamplona
26th-27th October

Organizing committee:
Sandra Hervás Stubbs, Pablo Sarobe, Alan Melcher, Ignacio Melero

INFORMATION: mcpinto@unav.es

Miltenyi Biotec S.L. | C/Luis Buñuel 2 | Ciudad de la Imagen | 28223 Pozuelo de Alarcón (Madrid), Spain
Phone +34 91 512 12 90 | Fax +34 91 512 12 91 | macs@miltenyibiotec.es | www.miltenyibiotec.com
Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS is a registered trademark of Miltenyi Biotec GmbH.



Scientific Program:

Tuesday, 26th October

9:15 h. Symposium Presentation by the organizing committee

Chairman

Juan José Lasarte, Centro de Investigación Médica Aplicada

9:30 h. Adoptive T cell transfer therapy for HIV and Cancer

Carl June, University of Pennsylvania

10:00 h. Mouse antiviral CTL and human alloantigenic CTL for functional studies: role of CD8 and of ROS generation in CTL activation and function

Alberto Anel, Universidad de Zaragoza

10:30 h. Bypassing tolerance to obtain high avidity TCR for gene therapy

Dolores Schendell, German Research Center for Environmental Health

11:00 h. Break

Chairman

Eduardo Olavarria, Hospital de Navarra

11:30 h. OX40 costimulation on Treg function

Mario Colombo, Fondazione IRCCS Istituto Nazionale Tumori



12:00 h. Understanding CD137-based immunotherapy of cancer
Ignacio Melero, Centro de Investigación Médica Aplicada y Clínica
Universidad de Navarra

12:30 h. Optimising agonistic antibodies to promote immune responses against cancer

Martin Glennie, University of Southampton

13:00 h. Generation of multiantigen-specific CD4+ and CD8+ T cells for adoptive immunotherapy

Mario Assembacher, Miltenyi Biotec GMBH

13:30 h. Lunch

Chairman

Felipe Prósper, Centro de Investigación Médica Aplicada y Clínica
Universidad de Navarra

16:30 h. The Immunogenic as well as cytotoxic potential of oncolytic viruses-from laboratory to clinic

Alan Melcher, Leeds Institute of Molecular Medicine

17:00 h. The power of T cells to reject large tumors

Tomas Blankenstein, Max-Delbrück-Center for Molecular Medicine

17:30 h. A peptide inhibitor of FOXP3 to improve vaccine efficacy

Noelia Casares, Centro de Investigación Médica Aplicada



Scientific Program:

Wednesday, 27th October

Chairman

Javier Pérez Calvo, Clínica Universidad de Navarra

9:00 h. Profiling the tumor microenvironment to identify strategies for overcoming tumor resistance to immunotherapy

Tomas Gajewski, University of Chicago

09:30 h. Effects of IFN-alpha as a signal-3 cytokine on human naïve and antigenexperienced CD8 T cells

Sandra Hervás, Centro de Investigación Médica Aplicada

10:00 h. Viral antigen processing for CD8+-T-lymphocyte-mediated *in vivo* control of infections

Margarita del Val, Centro de Biología Molecular Severo Ochoa (CSIC-UAM)

10:30 h. Clinical investigations with Poly-ICLC, a stabilized dsRNA Immunomodulator

Andrés Salazar, Oncovir

11:00 h. Break



Chairwoman

Susana Inogés, Clínica Universidad de Navarra

11:30 h. Adjuvant combination and antigen targeting as a strategy to enhance the efficacy of T cell responses

Pablo Sarobe, Centro de Investigación Médica Aplicada

12:00 h. Radiofrequency thermal ablation of Hepatocellular Carcinoma can activate adaptive and innate cell mediated immune response

Gabrielle Missale, Azienda Ospedaliero-Universitaria di Parma

12:30 h. Targeting Melanoma: Cellular Therapy, Small Molecules and their Combination

Eckhart Kämpgen, University Hospital Erlangen

13:00 h. Farewell